Article Text

Download PDFPDF

FRI0192 A SYSTEMATIC LITERATURE REVIEW TO INFORM THE 2019 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS
Free
  1. Antonis Fanouriakis1,
  2. Myrto Kostopoulou2,
  3. Alessia Alunno3,
  4. Martin Aringer4,
  5. Ingeborg Bajema5,
  6. John N. Boletis6,
  7. Ricard Cervera7,
  8. Andrea Doria8,
  9. Caroline Gordon9,
  10. Marcello Govoni10,
  11. Frederic Houssiau11,
  12. David Jayne12,
  13. Marios Kouloumas13,
  14. Annegret Kuhn14,
  15. Janni Lisander Larsen15,
  16. Kirsten Lerstrom16,
  17. Gabriela Moroni17,
  18. Marta Mosca18,
  19. Matthias Schneider19,
  20. Josef S. Smolen20,
  21. Elisabet Svenungsson21,
  22. Vladimir Tesar22,
  23. Angela Tincani23,
  24. Anne Troldborg24,
  25. Ronald van Vollenhoven25,
  26. Jörg Wenzel26,
  27. George Bertsias27,
  28. Dimitrios Boumpas1
  1. 1”Attikon” University Hospital, Athens, Greece
  2. 2”G. Gennimatas” General Hospital, Athens, Greece
  3. 3University of Perugia, Perugia, Italy
  4. 4University Medical Center and Faculty of Medicine Carl Gustav Carus at the TU Dresden, Dresden, Germany
  5. 5Leiden University Medical Center, Leiden, Netherlands
  6. 6”Laikon” Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece
  7. 7Hospital Clinic, Barcelona, Spain
  8. 8University of Padova, Padova, Italy
  9. 9Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom
  10. 10University of Ferrara, Azienda Ospedaliero-Universitaria Sant’Anna Ferrara, Ferrara, Italy
  11. 11Université catholique de Louvain, Brussels, Belgium
  12. 12University of Cambridge, Cambridge, United Kingdom
  13. 13Cyprus League Against Rheumatism, Aglantzia, Cyprus
  14. 14University Hospital Muenster, Muenster, Germany
  15. 15Rheumatology and Spine Diseases Centre, Rigshospitalet, Copenhagen, Denmark
  16. 16Lupus Europe, Farum, Denmark
  17. 17Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
  18. 18University of Pisa, Pisa, Italy
  19. 19UKD, Heinrich-Heine University, Düsseldorf, Düsseldorf, Germany
  20. 20Medial University of Vienna, Vienna, Austria
  21. 21Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
  22. 221st Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic
  23. 23University of Brescia, Brescia, Italy
  24. 24Aarhus University Hospital, Aarhus, Denmark
  25. 25Amsterdam University Medical Centers, Amsterdam, Netherlands
  26. 26University Hospital Bonn, Bonn, Germany
  27. 27University Hospital of Heraklion, Heraklion, Greece

Abstract

Background: Culminating evidence over the past decade regarding management of systemic lupus erythematosus (SLE) called for an update of the 2008 EULAR recommendations for the treatment of the disease.

Objectives: Systematic review of the literature (SLR) to inform the 2019 EULAR recommendations for the management of SLE.

Methods: SLR of Pubmed from 01/2007 to 12/2017 for questions (selected through Delphi excercise) regarding: i) efficacy/safety of different drugs used in SLE, ii) treatment of specific manifestations, iii) monitoring and treatment goals and iv) comorbidities and adjunct therapy. Evidence was categorised based on design and validity of available studies [Oxford Centre for Evidence-Based Medicine 2011 Levels of Evidence (LoE)] and strength of statements was graded [Grading of recommendation (GoR), assessment, development and evaluations, GRADE)].

Results: Main topics supported by strong evidence base included: Association of hydroxychloroquine (HCQ) use with favourable outcomes (LoE 1b, GoR A), belimumab for extrarenal disease (LoE 1a, GoR A), efficacy of antimalarials in skin disease (LoE 1a, GoR A), mycophenolate mofetil (MMF) for induction and maintenance therapy of lupus nephritis (LN) and cyclophosphamide (CYC) in severe LN (LoE 1b, GoR A). Weak evidence supported the value of repeat kidney biopsy in refractory LN (LoE 4, GoR C), all second-line agents for skin disease (LoE 4, GoR C) and efficacy of most first and second-line treatments for thrombocytopenia (LoE 4, GoR C). Moderate LoE was found for all other questions (Table).

Conclusion: A SLR for the treatment of SLE found the highest LoE for benefits of HCQ, efficacy of belimumab for extrarenal disease and MMF and IV-CYC in LN.

Acknowledgement: European League Against Rheumatism

Disclosure of Interests: Antonis Fanouriakis Paid instructor for: Amgen, GSK, Speakers bureau: Abbvie, Enorasis, Genesis Pharma, Myrto Kostopoulou: None declared, Alessia Alunno: None declared, Martin Aringer Grant/research support from: Roche, Consultant for: AstraZeneca and Eli Lilly, Ingeborg Bajema Consultant for: GSK, John N. Boletis: None declared, Ricard Cervera: None declared, Andrea Doria: None declared, Caroline Gordon Grant/research support from: Sandwell and West Birmingham Hospitals NHS Trust have received funding from UCB to support research work done by my research group that was unrelated to any pharmaceutical product or clinical trial., Consultant for: I have provided consultancy advice and taken part in scientific advisory boards on the design and analysis of clinical trials and the management of lupus for GSK, EMD Serono and UCB. I have taken part in adjudication and safety monitoring committees for BMS., Speakers bureau: I have been paid by UCB for speaking at meetings., Marcello Govoni Paid instructor for: Pfizer, Roche, Speakers bureau: Pfizer, Abbvie, MSD, Roche, Eli-Lilly, Celgene, Sanofi, Janssen, Frederic Houssiau: None declared, David Jayne Grant/research support from: David Jayne has received research grants from Chemocentryx, GSK, Roche/Genentech and Sanofi-Genzyme. He has received consultancy fees from Astra-Zeneca, Boehringer-Ingelheim, Chemocentryx, Chugai, GSK, Infla-RX, Insmed and Takeda, Marios Kouloumas: None declared, Annegret Kuhn Grant/research support from: Biogen, Galderma, GlaxoSmithKline, LeoPharma, Speakers bureau: La Roche Posay, Janni Lisander Larsen: None declared, Kirsten Lerstrom: None declared, Gabriela Moroni: None declared, Marta Mosca Paid instructor for: GlaxoSmithKline, Lilly, UCB, Matthias Schneider Grant/research support from: GlaxoSmithKline and UCB Pharma for performing the LuLa-study., Speakers bureau: Chugai, Josef S. Smolen Grant/research support from: AbbVie, Eli Lilly, Janssen, MSD, Pfizer Inc, Roche, Consultant for: AbbVie, Amgen, AstraZeneca, Astro, Celgene, Celtrion, Eli Lilly, GlaxoSmithKline, ILTOO, Janssen, Medimmune, MSD, Novartis-Sandoz, Pfizer Inc, Roche, Samsung, Sanofi, UCB, Speakers bureau: AbbVie, Amgen, AstraZeneca, Astro, Celgene, Celtrion, Eli Lilly, GlaxoSmithKline, ILTOO, Janssen, Medimmune, MSD, Novartis-Sandoz, Pfizer Inc, Roche, Samsung, Sanofi, UCB, Elisabet Svenungsson: None declared, Vladimir Tesar: None declared, Angela Tincani Consultant for: UCB, Pfizer, Abbvie, BMS, Sanofi, Roche, GSK, AlphaSigma, Lillly, Jannsen, Cellgene, Novartis, Anne Troldborg: None declared, Ronald van Vollenhoven Grant/research support from: AbbVie, Amgen, Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, Roche, and UCB, Consultant for: AbbVie, AstraZeneca, Biotest, Bristol-Myers Squibb, Celgene, Crescendo, GlaxoSmithKline, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, UCB, and Vertex., Speakers bureau: AbbVie, AstraZeneca, Biotest, Bristol-Myers Squibb, Celgene, Crescendo, GlaxoSmithKline, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, UCB, and Vertex., Jörg Wenzel Grant/research support from: GSK, Incyte, Consultant for: Biogen, Leo, Paid instructor for: Novartis, George Bertsias: None declared, Dimitrios Boumpas: None declared

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.